Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma.

Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effectively control the local lesion, it will inevitably lead to permanent blindness and facial appearance changes in patients, and there are still life-threatening risks.

Guangzhou Concord Cancer Center utilizes advanced pencil beam scanning proton therapy in combination with real-time image guidance system to achieve high-dose and accurate irradiation of target area, while maximizing the protection of important neighboring structures and allowing the patient to avoid enucleation. As the first medical institution in China to offer proton therapy for this condition, Guangzhou Concord Cancer Center has filled a critical gap in the field and provided a new eye-preserving treatment option for patients with choroidal malignant melanoma.

The Company previously announced the listing of Concord Healthcare's H shares on the HKSE on January 9, 2024.